This trial is evaluating whether Treatment will improve 1 primary outcome and 11 secondary outcomes in patients with Osteomyelitis. Measurement will happen over the course of Assessed 6 weeks post intervention.
This trial requires 880 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"There is no cure for osteomyelitis and only a small reduction in pain and progression of the illness, but this reduction is more marked in the subacute form of the disease at presentation." - Anonymous Online Contributor
"Fever and persistent pain over several days are good signs of an acute infection. Chronic osteomyelitis is the main clinical problem. The most common sign (and complication) is sepsis." - Anonymous Online Contributor
"Approximately 50 000 babies are affected by a new case of osteomyelitis per year in the United States. Osteomyelitis is a devastating disease and one that requires treatment very early in its course, preferably before diagnosis." - Anonymous Online Contributor
"Osteomyelitis is characterized by progressive destruction of bone and the presence of bone-borne infection. It can occur everywhere in the body but is most prevalent in the jaws, spine and pelvis. The diagnosis of osteomyelitis is often delayed and is often confused with skeletal metastasis. The symptoms vary as an infection progresses. The primary source of infection can be from dental procedures, genitourinary tract infection, open fracture, local trauma, prosthetic joint infection or prosthetic loosening resulting in a dislodged prosthesis." - Anonymous Online Contributor
"Osteomyelitis may have a number of causes. The presence of an open wound increases the risk for infection, whereas hematogenous spread of infection predisposes to osteomyelitis in the context of osteoporosis, immunocompromised, or immunosuppressed individuals." - Anonymous Online Contributor
"While antibiotic therapy can be helpful for treating localized osteomyelitis, in cases in which it is not possible to control locally on an individual basis, surgical intervention may be required to remove chronic implants and infected bone tissue. In all cases, long-term follow-up is essential to prevent the development of a second lesion." - Anonymous Online Contributor
"For osteomyelitis, patients that do not respond to conservative treatment with intravenous and/or oral antibiotics, that have signs or symptoms of complications related with healing bone tissue and who do not attain resolution with these first therapeutic interventions have the best likelihood of having a positive outcome after completing clinical trials." - Anonymous Online Contributor
"Most patients with [osteomyelitis] were receiving combination therapies with other treatments for more serious, chronic bone conditions. In patients with acute osteomyelitis, only 24% were treated solely with antibiotics." - Anonymous Online Contributor
"Osteomyelitis in OMX is a common and severe complication of this disease. The prevalence of osteomyelitis in OMX varies in the different countries, but it is much higher in North America than in Europe. The rate of osteomyelitis in OMX patients varies in different geographic areas and also between different autoinflammatory diseases. In contrast, the familial aggregation of OMX is reported only in the paediatric form of the disease. The aetiological factors in OMX patients differ from those found in the familial cases of the disease." - Anonymous Online Contributor
"The only new drug approved for osteomyelitis therapy is a daptomycin formulation for the treatment of Gram-negative infections. In addition, the Centers for Disease Control and Prevention has approved a number of different antibiotic combinations for treating osteomyelitis, including a single agent or poly-drug regimen of ceftazidime (CPX), ciprofloxacin, and clindamycin, or of vancomycin and daptomycin, or of vancomycin and rifampin for recalcitrant cases or when the infection is found to have become resistant to an initial regimen." - Anonymous Online Contributor
"Older age is a risk factor for developing osteomyelitis, but this cannot be entirely explained by increased BMI. The average age at presentation is 51 years, with the average peak age being 58 years. Most cases represent infection of bone from an asymptomatic primary source." - Anonymous Online Contributor
"Because the treatment of M. tsutsugamushi osteomyelitis is based on the observation of one author before the publication of an existing guideline in 1999, the results highlight two problems in clinical trials – first, the lack of inclusion of the other authors' data. Second, we propose that the authors have not conducted any clinical trials. Since there are no trials that have specifically been conducted to investigate the treatment of M. tsutsugamushi osteomyelitis, then the results of this guideline, which is based on the observation of one author, must, however, be considered inadequate for the treatment of M. tsutsugamushi osteomyelitis." - Anonymous Online Contributor